SAXENDA (liraglutide)
DIET AIDS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+1
NOVO NORDISK
Drug class
Anti-Obesity - GLP-1 and Dual GIP and GLP-1 Receptor Agonist
Anti-obesity glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists are incretin-mimetic pharmacotherapies utilized for chronic weight management. Read more about Anti-Obesity - GLP-1 and Dual GIP and GLP-1 Receptor Agonist
10 drugs in this class 6 manufacturers
Drugs in Anti-Obesity - GLP-1 and Dual GIP and GLP-1 Receptor Agonist
WEGOVY (semaglutide)
DIET AIDS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+3
NOVO NORDISK
ZEPBOUND (tirzepatide)
DIET AIDS · OBSTRUCTIVE SLEEP APNEA SYNDROME ·+2
Eli Lilly and Company
LIRAGLUTIDE
DIET AIDS · TYPE 2 DIABETES MELLITUS
TEVA PHARM
WEGOVY (semaglutide)
DIET AIDS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+3
A-S MEDICATION
ZEPBOUND KWIKPEN (tirzepatide)
DIET AIDS · OBSTRUCTIVE SLEEP APNEA SYNDROME ·+2
Eli Lilly and Company
LIRAGLUTIDE
DIET AIDS · TYPE 2 DIABETES MELLITUS
CIPLA USA, INC.
WEGOVY HD (semaglutide)
DIET AIDS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+3
NOVO NORDISK
FOUNDAYO (orforglipron calcium)
DIET AIDS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+1
Eli Lilly and Company
Filter & compare in the drug finder →
Opens the drug finder with Anti-Obesity - GLP-1 and Dual GIP and GLP-1 Receptor Agonist preselected. Add indication or manufacturer filters there.
Anti-obesity glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists are incretin-mimetic pharmacotherapies utilized for chronic weight management.
These agents function by activating gut hormone receptors in the central nervous system and gastrointestinal tract to enhance satiety, decrease appetite and energy intake, delay gastric emptying, and promote glucose-dependent insulin secretion.
Clinically, these agents are indicated as adjuncts to lifestyle modifications for individuals with obesity or overweight accompanied by weight-related comorbidities, such as hypertension, dyslipidemia, obstructive sleep apnea, and type 2 diabetes.
-
fda.gov
Anti-obesity glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists are incretin-mimetic pharmacotherapies utilized for chronic weight management These agents function by activating gut hormone receptors in the central nervous system and gastrointestinal tract to enhance satiety, decrease appetite and energy intake, delay gastric emptying, and promote glucose-dependent insulin secretion Clinically, these agents are indicated as adj...
-
frontiersin.org
Anti-obesity glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists are incretin-mimetic pharmacotherapies utilized for chronic weight management
-
nih.gov
These agents function by activating gut hormone receptors in the central nervous system and gastrointestinal tract to enhance satiety, decrease appetite and energy intake, delay gastric emptying, and promote glucose-dependent insulin secretion
-
nih.gov
Clinically, these agents are indicated as adjuncts to lifestyle modifications for individuals with obesity or overweight accompanied by weight-related comorbidities, such as hypertension, dyslipidemia, obstructive sleep apnea, and type 2 diabetes
-
fda.gov
Clinically, these agents are indicated as adjuncts to lifestyle modifications for individuals with obesity or overweight accompanied by weight-related comorbidities, such as hypertension, dyslipidemia, obstructive sleep apnea, and type 2 diabetes
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.